AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 222 min read$MRNA

Moderna, Merck Shares Fall After Possible Melanoma Data Leak

Moderna (MRNA) and Merck (MRK) shares fell after unverified reports suggested a possible data leak on their melanoma vaccine trial results, which are set to be released this weekend. Moderna's shares dropped 25%, while Merck's fell 3.9%. The companies had previously announced significant reductions in tumor recurrence when the vaccine was used with Merck's Keytruda drug.

Original reporting
finance.yahoo.com
Published Oct 22, 2026, 5:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 6:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$MRNA
Bearish
high confidence
Mentioned
$MRNA · $MRK
Relevance
8/10
AlphAI data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$MRNABearishHigh
01

Why it matters

The leak introduces uncertainty about efficacy results, prompting immediate price declines for both companies.

02

Market read

First‑report of data leak drives sharp short‑term moves; traders should monitor official trial release at ESMO.

03

What to watch

Regulatory review timelines and the upcoming ESMO presentation could mitigate long‑term impact.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

A Bloomberg report flagged a possible leak of trial data for a personalized melanoma vaccine being tested by Moderna in combination with Merck's Keytruda.

Company-level read

Ticker impact

$MRNABearishHigh confidence
Context

Moderna shares plunged up to 25% after reports of a possible leak of its personalized melanoma vaccine data.

Expected impact

downward pressure as investors reassess trial outlook

Evidence & confidence

First report of data leak; market reacts sharply with a 25% drop.

$MRKBearishHigh confidence
Context

Merck shares fell about 3.9% following the same melanoma vaccine data leak rumors.

Expected impact

moderate downside as uncertainty lingers

Evidence & confidence

Leak news is new and directly impacts Merck's partnership with Moderna.

Market effects

Sector

Biotech sector may see broader risk aversion pending data integrity concerns.

Regional

U.S. biotech stocks could face heightened volatility in early trading.

Global

International investors tracking oncology trials may adjust exposure.

Counterpoint

What could challenge this read

If the leak proves benign, the sell‑off could be overdone, offering a buying opportunity.

Key entities

  • company
    Moderna Inc.

    Biotech firm developing the personalized melanoma vaccine.

  • company
    Merck & Co.

    Pharma partner providing Keytruda for the trial.

Read at source← All news

StoryMerck and Moderna report positive Phase 3 melanoma vaccine results

Also covered by

6 outlets

Related articles

OCT 22
$MRKHighAI 8/10

RBC Capital reiterates Merck stock rating on melanoma trial data

RBC Capital reiterated a Sector Perform rating and $145 price target for Merck (MRK) after melanoma trial data showed a recurrence-free survival hazard ratio of 0.58. The stock is near its 52-week high, up 76% year-to-date. Analysts expect regulatory filings in the U.S. and Europe, with FDA approval anticipated in 2027. Merck is set to announce earnings on October 29, with mixed analyst expectations.

investing.com2 min
OCT 22
$MRNAHigh

Merck/Moderna cancer vaccine cuts melanoma death or recurrence risk by 42%, shares fall

Merck and Moderna reported that their combined mRNA cancer vaccine and immunotherapy reduced melanoma death or recurrence risk by 42% in a Phase 3 trial. Moderna shares fell 17% despite prior gains, while Merck shares dropped 1.8%. The vaccine, tested with Keytruda, showed significant efficacy, with 82.2% of patients cancer-free after two years. The companies plan to seek US approval and launch in 2027.

devdiscourse.com2 min
OCT 22
$MRNAHighAI 8/10

Why Moderna (MRNA) stock is trading lower today

Moderna (MRNA) stock fell 18.3% to $201.80 after partial Phase 3 data for its cancer vaccine with Merck leaked, showing positive results but causing a sell-off. The trial showed a 42% reduction in recurrence or death risk. Moderna's shares are volatile, up 551% YTD but down 18.2% from its 52-week high.

tradingview.com2 min